Top 10 Oncology Capital Raises in the U.S. – November 1st-15th, 2024
Several interesting transactions closed in the Oncology sector over the past 2 weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
- Lomond Therapeutics, developer of a biopharmaceutical platform designed to target escape mutations in hematological cancers, received $44 million of development capital from SIG, OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group, and other investors through a private placement.
- MAIA Biotechnology, a clinical-stage biopharmaceutical company, received $2.44 million of development capital through a private placement.
Merger/Acquisition and Corporate
- Lomond Therapeutics, developer of a biopharmaceutical platform designed to target escape mutations in hematological cancers, acquired Venetian-1 Acquisition Corp through a reverse merger.
Later Stage VC
- Calviri, developer of vaccines and peptides designed to facilitate diagnostics for early cancer detection, raised $935,004 in venture funding.
- Chemo Mouthpiece, developer of cryotherapy devices created to help alleviate the pain of oral mucositis, raised $5.9 million in venture funding from Sanara MedTech, Infusystem Holdings, and other investors.
- TRIO Pharmaceuticals, developer of a cancer immunotherapeutic antibody drug designed to generate immunogenic tumors, raised an estimated $6 million in venture funding from Myeloma Investment Fund, and other investors.
Early Stage VC
- CrossBridge Biom, developer of a biotechnology platform of antibody-drug conjugates intended to revolutionize cancer treatment, raised $10.82 million in venture funding in a deal led by Texas Medical Center and CE-Ventures.
- Serinus Biosciences, developer of an artificial intelligence platform designed to create combination therapies by rational design, raised a venture funding from Sapir Venture Partners.
Angel, Seed, and Grant
- MotleyBio, developer of a detection technology designed for diseases like cancer, raised a Series 1 pre-seed funding from Antler and Atlas SGR.
- RadioClash, developer of interventional oncology device intended to enhance electroporation therapy for advanced cancer therapeutics, raised $807,494 in seed funding. The funds will be used as working capital.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
